6-K
GSK plc (GSK)
6-K
2021-02-16
For: 2021-02-16
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in 2018 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions. Awards were made in 2018 and the three-year performance period commenced on 1 January 2018 and ended on 31 December 2020. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in 2018 are set out in the following table.
| Outcome<br>and Vesting Level | |||
|---|---|---|---|
| Portion<br>of the Award | Measure<br>and Outcome | % of<br>maximum | % of<br>award |
| 1/3rd | Adjusted Free Cash Flow - For the three-year period,<br>the Company achieved Adjusted Free Cash Flow calculated in<br>accordance with the principles for the measure of £15.64bn,<br>which is above the level of £12.60bn required for maximum<br>vesting.<br><br><br>Adjustments<br>to the original target and vesting schedule were communicated in<br>the 2019 Annual Report. | 100 | 33.333 |
| 1/3rd | Total Shareholder Return - For the three years ending<br>31 December 2020, the Company's Total Shareholder Return ranked<br>9th, which is below the threshold vesting level against a<br>comparator group of 10 global pharmaceutical companies including<br>GSK. | 0 | 0 |
| 1/3rd | R&D New Products - For the three-year period, the<br>Company achieved New Product sales calculated in accordance with<br>the principles for the measure of £7.337bn, which is above the<br>level of £4.387bn required for maximum vesting. The<br>threshold vesting level was £3.589bn. | 100 | 33.333 |
| Total vesting for 2018 award<br><br><br>Lapsed | 66.666%<br><br><br>33.334% |
The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 11 February 2021. The balance of the award made to each PDMR and PCA has lapsed.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on the vesting date were £12.552 and $35.52.
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Ms E Walmsley | ||
| b) | Position/status | Chief<br>Executive Officer | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 340,753 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr H Barron | ||
| b) | Position/status | Chief<br>Scientific Officer and President, R&D | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The number of ADSs vesting on awards granted in 2018 under the<br>Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $0.00 | 180,833 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr R Connor | ||
| b) | Position/status | President, Global Vaccines | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary Shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 135,107 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms D Conrad | ||
| b) | Position/status | SVP,<br>Human Resources | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 9,181 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr J Ford | ||
| b) | Position/status | SVP<br>& General Counsel | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The number of ADSs vesting on awards granted in 2018 under the<br>Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $0.00 | 5,229 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr N Hirons | ||
| b) | Position/status | SVP,<br>Global Ethics and Compliance | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 50,108 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms S Jackson | ||
| b) | Position/status | SVP,<br>Global Communications & CEO Office | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 9,181 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr D Jackson | ||
| b) | Position/status | PCA<br>of Ms S Jackson (SVP,<br>Global Communications & CEO Office) | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 4,335 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr B McNamara | ||
| b) | Position/status | CEO,<br>GSK Consumer Healthcare | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The number of ADSs vesting on awards granted in 2018 under the<br>Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $0.00 | 84,162 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr L Miels | ||
| b) | Position/status | President,<br>Global Pharmaceuticals | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 175,482 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr D Redfern | ||
| b) | Position/status | Chief Strategy Officer | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 92,622 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr R Simard | ||
| b) | Position/status | President,<br>Pharmaceuticals Supply Chain | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 9,181 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms K Terrell | ||
| b) | Position/status | Chief<br>Digital & Technology Officer | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The number of ADSs vesting on awards granted in 2018 under the<br>Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $0.00 | 69,781 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr P Thomson | ||
| b) | Position/status | President,<br>Global Affairs | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 66,043 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms D Waterhouse | ||
| b) | Position/status | CEO, ViiV Healthcare | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 12,589 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms V Whyte | ||
| b) | Position/status | Company<br>Secretary | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The number of Ordinary Shares vesting on awards granted in 2018<br>under the Company's 2017 Performance Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 9,181 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2021-02-11 | ||
| f) | Place<br>of the transaction | N/A |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: February<br>15, 2021 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |